With key data presented at this year’s 63rd Annual American Society of Hematology Meeting and Exposition showing several CAR T-cell therapies as effective and safe options in the second- and even first-line setting for multiple myeloma and other cancers, discussions on when to best to use these therapies in the real-world setting has garnered increasing attention by payers and providers.

At ASH 2021, we sat down with several key opinion leaders to discuss the use of real-world data for CAR T-cell therapies and its importance in influencing reimbursement and investment strategies by payers.